# EDGAR Filing Document

**Accession Number:** 0001530766
**File Stem:** 0001493152-25-028606
**Filing Date:** 2025-12
**Character Count:** 20130
**Document Hash:** 3c25206e46489633179dbb5364bc7399
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-028606.hdr.sgml**: 20251219

**ACCESSION NUMBER**: 0001493152-25-028606

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 34

**CONFORMED PERIOD OF REPORT**: 20251216

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251219

**DATE AS OF CHANGE**: 20251219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Streamex Corp.
- **CENTRAL INDEX KEY:** 0001530766
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 264333375
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38659
- **FILM NUMBER:** 251588591

**BUSINESS ADDRESS:**
- **STREET 1:** 2431 ALOMA AVENUE
- **STREET 2:** SUITE 243
- **CITY:** WINTER PARK
- **STATE:** FL
- **ZIP:** 32792
- **BUSINESS PHONE:** (203) 409-5444

**MAIL ADDRESS:**
- **STREET 1:** 2431 ALOMA AVENUE
- **STREET 2:** SUITE 243
- **CITY:** WINTER PARK
- **STATE:** FL
- **ZIP:** 32792

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioSig Technologies, Inc.
- **DATE OF NAME CHANGE:** 20110921

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 16, 2025

**<u>STREAMEX CORP.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38659** | **26-4333375** |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |

---

**2431 Aloma Avenue, Suite 243**

**Winter Park, Florida 32792**

(Address of principal executive offices)

**90025**

(Zip Code)

**<u>(203) 409-5444</u>**

(Registrant's telephone number, including area code)

**<u>N/A</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of exchange on which registered** |
| Common Stock, par value $0.001 per share | STEX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

***Amendment to Secured Convertible Debenture Purchase Agreement and Second Closing***

As previously disclosed in the Current Report on Form 8-K filed by Streamex Corp. (f./k/a BioSig Technologies, Inc.), a Delaware corporation (the "Company") with the Securities and Exchange Commission on July 9, 2025, August 13, 2025, and October 28, 2025, November 6, 2025 (combined together the "Prior Form 8-Ks"), the Company entered into a certain Secured Convertible Debenture Purchase Agreement with YA II PN, LTD., a Cayman Islands exempt limited company ("Yorkville" or the "Investor"), for the issuance and sale by the Company of convertible debentures (the "Convertible Debentures," each, a "Convertible Debenture"), which Convertible Debentures will be convertible into shares of the Company's common stock, par value $0.001 per share (the "Common Stock") (as converted, the "Conversion Shares"), as amended on August 13, 2025 by Amendment No. 1 to the Secured Convertible Debenture Purchase Agreement, on October 28, 2025 by Amendment No. 2 to the Secured Convertible Debenture Purchase Agreement, on November 4, 2025 by Amendment No. 3 to the Secured Convertible Debenture Purchase Agreement together, hereinafter referred to as the "Debenture Purchase Agreement"). Further to this, on December 17, 2025, the Company entered into a certain Amendment No. 4 to the Debenture Purchase Agreement (the "Fourth Amendment") with Yorkville. The Fourth Amendment further amends the Debenture Purchase Agreement, amending certain prior closing conditions with no material terms amended.

Further to this, on December 17, 2025 (the "Second Closing Date"), the Company issued the second tranche of Convertible Debenture to Yorkville with a principal amount of $25,000,000 (the "Second Convertible Debenture"), on similar terms as the initial tranche of Convertible Debenture to Yorkville, dated November 4, 2025, as disclosed in our Prior Form 8-Ks. The Second Convertible Debenture will mature on December 17, 2027, and will accrue interest at the rate of 4.00% per annum, which will increase to 18.00% per annum upon the occurrence of an event of default, until such event of default is cured. The principal must be paid in cash on the maturity date or earlier upon acceleration or conversion. Interest shall be provided in cash or, at the election of the Company, in kind through the issuance of Conversion Shares upon conversion of the Second Convertible Debenture in accordance with the terms thereof. The Second Convertible Debenture provides that the Investor may convert all or any portion of the principal amount of the Convertible Debenture, together with any accrued and unpaid interest thereon, at a conversion price equal to the lower of (i) $6.016 per Common Stock; a fixed price per share equal to 125% of the volume-weighted average price ("VWAP") of the Common Stock on November 3, 2025, be subject to a one-time, downward only reset equal to 125% of the average of the daily VWAP for the Common Stock during the five consecutive trading days ending on and including the 30th trading day following the effectiveness of the registration statement registering the resale of the Conversion Shares as described below (the "Resale Registration Statement"), and (ii) 97.0% of the lowest daily VWAP for the Common Stock during the three trading days immediately preceding the applicable conversion date or other date of determination, subject to a floor price equal to $4.00 per Common Stock, in each case subject to adjustment as provided in the Convertible Debenture, including adjustments for stock splits, dividends, and other customary anti-dilution provisions. The Second Convertible Debenture resulted in gross proceeds to the Company of approximately $24,000,000, representing 96.0% of the principal amount of each Convertible Debenture.

The Company has the option to prepay, in part or in whole, the outstanding principal and interest under the Second Convertible Debenture prior to the maturity date, plus a prepayment premium of 10% of the principal amount of the applicable Second Convertible Debenture, provided that the Company delivers at least ten trading days' prior written notice of such prepayment, during which period the holder retains the right to convert all or any portion of the Second Convertible Debenture. The Second Convertible Debenture also provide for certain rights of the holder in the event the Company issues additional securities or incurs additional indebtedness, subject to the covenants set forth in the transaction documents. Standard events of default are included in the Second Convertible Debenture, pursuant to which the holder may declare the Second Convertible Debenture immediately due and payable and exercise other remedies, including the right to foreclose on the collateral securing the obligations. The Debenture Purchase Agreement also contains customary representation and warranties of the Company and the Investor, indemnification obligations of the Company, termination provisions, and other obligations and rights of the parties. The Investor shall not have the right to convert any portion of the Second Convertible Debenture if, after giving effect to such conversion, the Investor, together with its affiliates, would beneficially own more than 4.99% of the outstanding Common Stock immediately following such conversion, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules promulgated thereunder.

The foregoing descriptions of the Second Convertible Debenture, and the Fourth Amendment, do not purport to be complete and are qualified in their entirety by reference to the full text of such documents, which are filed or referenced hereof as Exhibits 4.1, and 10.1 respectively, and are incorporated herein by reference.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The information contained in Item 1.01 is incorporated herein by reference.

**Item 3.02 Unregistered Sales of Equity Securities.**

The information contained in Item 1.01 is incorporated herein by reference. The issuance of the Second Convertible Debenture was, and the Conversion Shares issuable upon conversion of the Second Convertible Debenture will be, exempt from registration pursuant to Section 4(a)(2) of the Securities Act. Yorkville represented to the Company that it is an "accredited investor" as defined in Rule 501 of the Securities Act and that each of the Second Convertible Debenture and the Conversion Shares will be acquired for investment purposes and not with a view to, or for sale in connection with, any distribution thereof.

**Item 8.01 Other Events**

On December 16, 2025, the Company hosted a corporate update webinar the investor presentation from which is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference. The Company expects to use the investor presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others.

The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Investor Presentation speaks only as of the date of this current report on Form 8-K. The Company undertakes no duty or obligation to publicly update or revise the information included in the Investor Presentation, although it may do so from time to time. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or other public disclosure. In addition, the exhibit furnished herewith contains statements intended as "forward-looking statements" that are subject to the cautionary statements about forward-looking statements set forth in such exhibit. By furnishing the information contained in the Investor Presentation, the Company makes no admission as to the materiality of any information in the Investor Presentation that is required to be disclosed solely by reason of Regulation FD.

**Item 9.01 Financial Statements and Exhibits**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 4.1 | [Secured Convertible Debenture, issued to YA II PN, Ltd., dated November 4, 2025 (incorporated by reference to Exhibit 4.1 in the Form 8-K filed with the SEC on November 6, 2025).](https://www.sec.gov/Archives/edgar/data/1530766/000149315225021102/ex4-1.htm) |
| 10.1 | [Amendment No. 4 to Secured Convertible Debenture Purchase Agreement, dated as of December 17, 2025, between the Company and YA II PN, Ltd.](ex10-1.htm) |
| 99.1 | [Investor Presentation, dated December 16, 2025.](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 19, 2025

---

| | |
|:---|:---|
| **STREAMEX CORP.** | **STREAMEX CORP.** |
| By: | */s/ Karl Henry McPhie* |
| Name: | Karl Henry McPhie |
| Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**<u>AMENDMENT NO. 4 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT</u>**

This AMENDMENT NO. 4 TO SECURED CONVERTIBLE DEBENTURE PURCHASE AGREEMENT (this "Amendment") is made and entered into as of December 17, 2025, by and between **STREAMEX CORP.** (f/k/a/ **BIOSIG TECHNOLOGIES, INC.**), a company incorporated under the laws of the State of Delaware, with principal executive offices located at 2431 Aloma Ave., Ste. 243, Winter Park, FL 32792 (the "<u>Company</u>"), and YA II PN, Ltd. (the "<u>Buyer</u>") and as collateral agent (in such capacity, the "<u>Collateral Agent</u>").

<u>RECITALS</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. Buyer and Company have entered into that certain Secured Convertible Debenture Purchase Agreement dated as of July 7, 2025, as amended on August 13, 2025, and October 28, 2025, November 4, 2025 (as amended, the "<u>Agreement</u>").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. Buyer and Company desire to amend the Agreement in accordance with the terms and conditions set forth below.

<u>AGREEMENT</u>:

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Buyer and Company hereby agree that, notwithstanding anything to the contrary contained in the Agreement, the Agreement shall be amended as set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Defined Terms</u>. All capitalized terms used herein and not otherwise defined shall have the meanings respectively ascribed to them in the Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Amendments</u>. Pursuant to <u>Section 10(f)</u> of the Agreement, the Parties agree to amend the Agreement as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. <u>Section 4(v)</u> of the Agreement, as set forth below, shall be deleted in its entirety:

The Company shall have obtained the Streamex Registration Right Waivers duly executed by Streamex Non-Affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. <u>Section 3(e)</u> of the Agreement shall be replaced in its entirety by the following:

The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other Governmental Entity or other person or entity ("<u>Person</u>") in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filing with the SEC the registration statement for the resale of the Conversion Shares (the "<u>Resale Registration Statement</u>"), (ii) notifications required by the Principal Market, and (iii) the failure of which to obtain would not be reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect or a material adverse effect on the Company's ability to consummate the transactions contemplated hereby, including the sale and issuance of the Securities(collectively, the "<u>Required Approvals</u>"). "<u>Governmental Entity</u>" means any nation, state, province, territory, county, city, town, village, district, or other political jurisdiction of any nature, federal, state, provincial, territorial, local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or body; or body exercising, or entitled to exercise, any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise owned or controlled by a government or a public international organization or any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. <u>Section 7(a)(xxvi)</u> of the Agreement, as set forth below, shall be deleted in its entirety:

The Company shall of delivered to the Buyer and Placement Agents the Streamex Registration Right Waivers duly executed by the Streamex Non-Affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Full Force and Effect</u>. Except as specifically amended hereby, the Agreement remains in full force and effect and is hereby ratified by Buyer and Company. In the event that any of the terms or conditions of the Agreement conflict with this Amendment, the terms and conditions of this Amendment shall control. Unless the context otherwise requires, all references in this Agreement to "this Agreement" mean the Agreement, as amended by this Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Counterparts</u>. This Amendment may be executed in two (2) or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. In the event that any signature is delivered by an email which contains a portable document format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

**IN WITNESS WHEREOF,** the parties have executed this Amendment as of the date first set forth above.

---

| | | | |
|:---|:---|:---|:---|
| **BUYER AND COLLATERAL AGENT:** | **BUYER AND COLLATERAL AGENT:** | **COMPANY**: | **COMPANY**: |
| **YA II PN, LTD.,** | **YA II PN, LTD.,** | **STREAMEX CORP. (f/k/a/** | **STREAMEX CORP. (f/k/a/** |
| a Cayman Islands exempt limited company | a Cayman Islands exempt limited company | **BIOSIG TECHNOLOGIES, INC.)** | **BIOSIG TECHNOLOGIES, INC.)** |
| By: | Yorkville Advisors Global, LP |  |  |
| Its: | Investment Manager |  |  |
| By: | /s/ *Troy Rillo* | By: | */s/ Karl Henry McPhie* |
| Name: | Troy Rillo | Name: | Karl Henry McPhie |
| Title: | Partner | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

![](ex99-1_002.jpg)

![](ex99-1_003.jpg)

![](ex99-1_004.jpg)

![](ex99-1_005.jpg)

![](ex99-1_006.jpg)

![](ex99-1_007.jpg)

![](ex99-1_008.jpg)

![](ex99-1_009.jpg)

![](ex99-1_010.jpg)

![](ex99-1_011.jpg)

![](ex99-1_012.jpg)

![](ex99-1_013.jpg)

![](ex99-1_014.jpg)

![](ex99-1_015.jpg)

![](ex99-1_016.jpg)

![](ex99-1_017.jpg)

![](ex99-1_018.jpg)

![](ex99-1_019.jpg)

![](ex99-1_020.jpg)